Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8640560 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL3558101 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL6050828 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL10891279 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL2569149 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL8640554 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL2229452 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL3658217 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL4712511 | 1.00 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNAHTR6 | |
| SCHEMBL157427 | 0.98 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146224-A | Nitrogen-containing tricyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117720517-A | AR inhibitor, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024012570-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-01-18 | — | — | WO | claimed |
| WO-2023232133-A1 | COMPOUND FOR INHIBITING OR DEGRADING BCL6 AND USE THEREOF IN PHARMACEUTICS | 西藏海思科制药有限公司 | 2023-12-07 | — | — | WO | claimed |
| WO-2023208165-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2023-11-02 | — | — | WO | claimed |
| CN-116969921-A | Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116947877-A | Benzimidazole derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-27 | — | — | CN | claimed |
| EP-3873599-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-27 | — | — | EP | claimed |
| US-11639352-B2 | Benzothiazole compounds for the treatment of autoimmune diseases | HOFFMAN-LA ROCHE INC. (US) | 2023-05-02 | — | — | US | claimed |
| CN-114920746-A | BTK (BTK inhibitory or degrading agent) and application thereof in medicine | 四川海思科制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| WO-2005089747-A1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2005-09-29 | — | — | WO | claimed |
| US-6908929-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-06-21 | — | — | US | claimed |
| US-20050090523-A1 | 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example | BREITENBUCHER J G (US) | 2005-04-28 | — | — | US | claimed |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | claimed |
| US-6734306-B2 | USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE | PFIZER, INC. | 2004-05-11 | — | — | US | claimed |
| EP-1268478-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| US-20020128271-A1 | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | PFIZER INC. | 2002-09-12 | — | — | US | claimed |
| EP-1213289-A1 | N-benzenesulfonyl L-proline compounds as bradykinin antagonists | PFIZER INC. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | claimed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | CYP2D6 46/4885MEN1 4485/4885KMT2A 2545/4885 |
| US-20020128271-A1 | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | BDKRB1, HRH2, BDKRB2 | CYP2D6 2011/4885MEN1 3988/4885KMT2A 2975/4885 |
| US-20050090523-A1 | 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example | HRH3, HRH4, HTR2C | CYP2D6 681/4885MEN1 3966/4885KMT2A 57/4885 |
| US-11639352-B2 | Benzothiazole compounds for the treatment of autoimmune diseases | SSB, BET1, HLA-DRB1 | CYP2D6 1560/4885MEN1 328/4885KMT2A 963/4885 |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | CYP2D6 46/4885MEN1 4485/4885KMT2A 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.